Background
==========

Riociguat is the first oral, soluble guanylate cyclase stimulator licensed for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension \[[@B1]-[@B3]\]. For some patients with PAH, e.g. children and the elderly, swallowing tablets may be inappropriate or difficult; therefore, oral suspension and crushed tablet formulations of riociguat were developed. Here we present data from two single-centre, randomised, non-blinded, crossover studies evaluating the relative bioavailability of riociguat as oral liquid and standard "immediate release" (IR) oral tablet under fed and fasted conditions, and as a crushed-tablet preparation versus oral tablet under fasted conditions.

Methods
=======

In Study 1, 30 healthy male and female volunteers received five single doses of riociguat in a randomised order: 0.3 and 2.4 mg riociguat (0.15 mg/mL suspension), 0.15 mg riociguat (0.03 mg/mL suspension), and 1.0 mg riociguat IR tablet (all in a fasted state), and 2.4 mg riociguat (0.15 mg/mL suspension) after a high-calorie breakfast. In Study 2, 25 healthy male volunteers received four single doses of riociguat 2.5 mg in a randomised order: oral IR tablet with water and crushed tablet suspended in applesauce or crushed tablet suspended in water (all fasted), and oral whole IR tablet after a continental breakfast. Repeated blood samples for pharmacokinetic assessment were taken. Both studies also assessed safety and tolerability.

Results
=======

In Study 1, dose-normalised pharmacokinetic parameters of riociguat suspensions were almost identical to the standard 1.0 mg IR tablet in fasted conditions (Table [1](#T1){ref-type="table"}); 90% confidence intervals for the ratio 'suspension/IR tablet' area under concentration (AUC) versus time curve and maximum drug concentration in plasma (C~max~) of riociguat were within the bioequivalence reference range (80--125%). After food intake, dose-normalised AUC and C ~max~decreased by 15% and 38%, respectively. In Study 2, riociguat exposure of the 2.5 mg IR tablet was similar for all four modes of administration (Table [2](#T2){ref-type="table"}); AUC ratios 'crushed tablet suspended in water or applesauce/IR tablet' were within bioequivalence criteria. C~max~ was increased by 17% after administration of crushed tablet suspended in water. Food intake decreased C~max~ of riociguat IR tablet by 16% with unaltered AUC versus the fasted state. The most frequently reported drug-related adverse events (AEs) were related to riociguat mode of action, notably headache (Study 1: 30--47%; Study 2: 13--20%). There were no deaths, serious AEs or withdrawals owing to AEs.

###### 

Study 1: Pharmacokinetic parameters of riociguat in plasma after a single oral dose of riociguat (pharmacokinetic analysis population, n=29):

  Parameter   Unit     n    2.4 mg high-concentration suspension fasted   n    2.4 mg high-concentration suspension fed   n    0.3 mg high-concentration suspension fasted   n    0.15 mg low-concentration suspension fasted   n    mgIR tablet fasted
  ----------- -------- ---- --------------------------------------------- ---- ------------------------------------------ ---- --------------------------------------------- ---- --------------------------------------------- ---- ----------------------
  AUC         μ\*h/L   29   781/49 (230--1515)                            29   663/45 (258--1212)                         27   91/43 (38--165)                               25   47/60 (8.3--91)                               29   311/46 (103--587)
                                                                                                                                                                                                                                     
  AUC/D       h/L      29   0.33/49 (0.10--0.63)                          29   0.28/45 (0.12--0.50)                       27   0.30/43 (0.13--0.55)                          25   0.31/60 (0.056--0.61)                         29   0.31/46 (0.10--0.59)
                                                                                                                                                                                                                                     
  C~max~      μ/L      29   78/31 (43--128)                               29   48/22 (32--70)                             29   9.8/33 (4.5--17)                              29   4.9/35 (1.9--8.1)                             29   36/30 (18--61)
                                                                                                                                                                                                                                     
  C~max~/D    1/L      29   0.03/31 (0.02--0.05)                          29   0.02/22 (0.01--0.29)                       29   0.03/33 (0.01--0.06)                          29   0.03/35 (0.01--0.05)                          29   0.04/30 (0.02--0.06)
                                                                                                                                                                                                                                     
  t~max~^a^   h        29   1.5 (0.75--4.0)                               29   4.0 (3.0--12)                              29   1.0 (0.50--3.0)                               29   1.0 (0.50--4.0)                               29   1.0 (0.50--3.0)
                                                                                                                                                                                                                                     
  t~1/2~      h        29   9.2/41 (2.8--21)                              29   9.4/33 (4.2--17)                           27   7.8/39 (3.5--15)                              25   6.8/42 (2.5--12)                              29   7.9/43 (3.4--14)

Data presented as geometric mean/% coefficient of variation (range) unless otherwise specified.

^a^ Median (range)

AUC, area under the concentration versus time curve; AUC/D; AUC divided by dose; C~max~, maximum drug concentration in plasma; C~max~/D: C~max~ divided by dose; IR, immediate-release; t~max~; time to reach Cmax; t~1/2~; half life

###### 

Study 2: AUC and C~max~ ratios of 'crushed tablet suspended in water or applesauce/whole IR tablet' (fasted) and 'whole IR tablet fed/whole IR tablet fasted' after a single oral dose of riociguat (pharmacokinetic analysis population, n=24):

  Ratio                                                          Parameter   Unit     CV      Estimated ratio (%)   90% CI
  -------------------------------------------------------------- ----------- -------- ------- --------------------- ------------
  Crushed tablet suspended in applesauce/whole tablet fasted     AUC         μ\*h/L   16.76   98                    (91--107)
                                                                 C~max~      μ/L      18.77   88                    (80-- 96)
  Crushed tablet suspended in water/whole tablet fasted          AUC         μ\*h/L   16.76   103                   (95--112)
                                                                 C~max~      μ/L      18.77   117                   (107--128)
  Whole tablet fed (continental breakfast)/whole tablet fasted   AUC         μ\*h/L   16.76   96                    (89--104)
                                                                 C~max~      μ/L      18.77   84                    (77--92)

AUC, area under the concentration versus time curve; C~max~, maximum drug concentration in plasma

CI, confidence interval; CV, coefficient of variation; IR, immediate release

Conclusions
===========

Riociguat bioavailability was similar between the high- (0.15 mg/mL) and low- (0.03 mg/mL) concentration suspensions and the IR tablet. Riociguat exposure was also similar between whole IR tablet and the crushed tablet suspended either in water or applesauce. Minor food effects were observed for the high-concentration (2.4 mg) suspension and the 2.5 mg IR tablet, but overall the pharmacokinetic results suggest that riociguat formulations are interchangeable.
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